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Wilson GJ, Bunpo P, Cundiff JK, Wek RC, Anthony TG. The
eukaryotic initiation factor 2 kinase GCN2 protects against hepato-
toxicity during asparaginase treatment. Am J Physiol Endocrinol
Metab 305: E1124–E1133, 2013. First published September 3, 2013;
doi:10.1152/ajpendo.00080.2013.—Asparaginase is an important drug
in the treatment regimen for acute lymphoblastic leukemia. Aspara-
ginase depletes circulating asparagine and glutamine, activating an
amino acid stress response (AAR) involving phosphorylation of
eukaryotic initiation factor 2 (eIF2) by general control nonderepress-
ible kinase 2 (GCN2). We hypothesized that GCN2 functions to
mitigate hepatic stress during asparaginase therapy by activating the
AAR. To test this idea, C57BL/6J wild-type mice (Gcn2/) and
those deleted for Gcn2 (Gcn2/) were injected with asparaginase or
saline excipient one time daily for 1 or 6 days. In liver, increased
phosphorylation of eIF2 and mRNA expression of AAR target genes
activating transcription factor 4, asparagine synthetase, eIF4E-
binding protein 1, and CAAT enhancer-binding protein homologous
protein were significantly blunted or blocked in the liver of Gcn2/
mice. Loss of AAR during asparaginase coincided with increases
in mammalian target of rapamycin signaling, hepatic triglyceride
accumulation, and DNA damage in association with genetic mark-
ers of oxidative stress (glutathione peroxidase) and inflammation
(tumor necrosis factor alpha-). Although asparaginase depleted
circulating asparagine in both Gcn2/ and Gcn2/ mice, all
other amino acids, including plasma glutamine, were elevated in
the plasma of Gcn2/ mice. This study shows that loss of GCN2
promotes oxidative stress and inflammatory-mediated DNA dam-
age during asparaginase therapy, suggesting that patients with
reduced or dysfunctional AAR may be at risk of developing hepatic
complications during asparaginase treatment.
eukaryotic initiation factor 2; liver; steatosis; amino acid stress re-
sponse; endoplasmic reticulum stress
ACUTE LYMPHOCYTIC LEUKEMIA (ALL), the most common child-
hood cancer, is caused by DNA alterations that lead to the
overproduction of immature leukemic lymphoblasts from the
bone marrow (43). Bacterial (Escherichia coli) L-asparaginase
has been an essential component of the remission induction
regimen to treat ALL since the 1960s (48). The efficacy of this
therapy is dependent on the depletion of circulating asparagine,
depriving tumor cells of an amino acid that it requires exoge-
nously. While treatment success in ALL patients has signifi-
cantly improved over the past two decades, the therapy retains
a highly toxic profile (18). Among the major toxicities associ-
ated with asparaginase are hepatotoxicity (10, 20), thrombosis
(1, 4, 31), immunosuppression (12, 14), and pancreatitis (30,
40). The underlying basis for these pathophysiologies and
additional adverse metabolic events to asparaginase are still not
well understood.
The general control nonderepressible kinase 2 (GCN2) is a
member of a family of four eukaryotic initiation factor 2 (eIF2)
kinases that become activated in response to diverse cellular
stresses (56). Upon depletion for amino acids, GCN2 phos-
phorylates eIF2, lowering general protein synthesis to reduce
energy expenditure. Accompanying this reduced translation,
eIF2 phosphorylation facilitates the preferential expression of a
collection of stress-related genes, such as activating transcrip-
tion factor 4 (ATF4) (52, 62). Increased promoter binding by
ATF4 and other trans-acting factors escalates the transcrip-
tional expression of genes involved in amino acid metabolism,
nutrient uptake, redox status, and cell cycle control in a
pathway described as the integrated stress response (24, 25) or,
alternatively, when specifically referring to amino acid deple-
tion, the amino acid stress response (AAR) (8, 9). The trans-
lational and transcriptional gene expression directed by eIF2
phosphorylation helps the cell regain homeostasis or guide it
toward death pathways if the underlying stress is unrecover-
able. GCN2 functions as a sensor of amino acid levels by
directly detecting the presence of deacylated or “uncharged”
tRNA that accumulate during nutrient depletion (7, 23, 27, 62).
Mice deleted for Gcn2 fail to phosphorylate eIF2 during
dietary leucine starvation and develop fatty liver before be-
coming moribund (3, 21). Thus loss of GCN2 renders an
organism less capable of adapting to a brief period of depri-
vation for dietary essential amino acids (60).
Cellular deprivation of amino acids is also sensed by the
mammalian target of rapamycin complex 1 (mTORC1) signal-
ing pathway (63). Phosphorylation of mTORC1 and its down-
stream effectors, ribosomal protein S6 kinase (S6K1) and eIF
4E-binding protein 1 (4E-BP1), function together to drive
changes in translational efficiency and ribosomal capacity in
response to amino acid availability (2, 17, 63). Notably, tran-
scriptional expression of the translational inhibitor 4E-BP1 is
enhanced by ATF4 (58), establishing a point of coordination
between the eIF2 kinase and mTORC1 pathways during envi-
ronmental stress. Deletion of Gcn2 disrupts the mTORC1
signaling network, altering phosphorylation of 4E-BP1 and
S6K1 to conditions of amino acid deprivation (3, 13). How
deletion of Gcn2 alters mTORC1 signaling and 4E-BP1 gene
transcription during asparaginase is not well understood.
Previous work from our laboratory demonstrates that a
single injection of asparaginase depletes asparagine and glu-
tamine in the blood and liver of wild-type mice (44). In liver,
increased phosphorylation of eIF2 and reduced phosphoryla-
tion of S6K1 and 4E-BP1 by asparaginase requires GCN2 (13).
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Nevertheless, long-term hepatic consequences of asparaginase
treatment in the absence of GCN2 remain unclear. In the
spleen, thymus, and bone marrow, the absence of GCN2 ampli-
fies immunosuppression triggered by asparaginase therapy
(12). Based on these observations, we hypothesized that mice
deleted for Gcn2 would demonstrate greater hepatotoxicity
following longer-term asparaginase treatment. Furthermore,
based on the report by Hernandez-Espinosa and colleagues
defining asparaginase as a “temporary conformational disease”
(26), the potential of asparaginase to induce endoplasmic re-
ticulum (ER) stress in the presence or absence of Gcn2 was
investigated.
METHODS
Measurement of L-asparaginase activity. The activity of asparagi-
nase derived from E. coli (Elspar; Merck) was determined by the
Nesslerization technique, as previously described (12, 44). Briefly, the
production of ammonia by asparaginase over time was expressed
relative to the slope of known ammonia standards. The resulting
values represented the activity of the enzyme in international units
(IU), in which one IU equaled the amount of enzyme that catalyzed
the formation of 1 mol of ammonia/min.
Animals. Male and female Gcn2 knockout mice (backcrossed to
C57BL/6J for 10 generations) and wild-type C57BL/6J control mice
(Jackson Laboratories, Bar Harbor, ME) age 6–10 wk were housed in
plastic cages with soft bedding with a 12:12-h light-dark cycle and
given free access to commercial rodent chow (PMI International,
Brentwood, MO) and water. All animal protocols were approved by
the institutional animal care and use committees at the Indiana
University School of Medicine-Evansville and at Rutgers, The State
University of New Jersey.
Experimental procedure. Mice from both genetic strains received
once-daily intraperitoneal injections of either L-asparaginase (3 IU/g
body wt) or an equivalent volume of phosphate-buffered saline (PBS)
for 1 or 6 days. The daily dosage was based on an understanding that
mice are more resistant to asparaginase because of a shorter half-life
(3–7 h vs.20 h in humans) (6, 11) in combination with our previous
work showing 3 IU/g to increase eIF2 phosphorylation, whereas doses
2 IU/g do not (44). The experimental design resulted in four
treatment groups: WP, C57BL/6J wild-type mice injected with PBS;
WA, wild-type mice injected with asparaginase; GP, Gcn2 null mice
injected with PBS; and GA, Gcn2 null mice injected with asparagi-
nase. Previous experiments comparing heat-killed asparaginase with
saline excipient alone established PBS as an appropriate control (12).
Six hours after the final injection, mice were killed by decapitation,
and trunk blood was collected to produce serum. Whole organs or
tissues were rapidly dissected, rinsed in ice-cold PBS, blotted, and
weighed. One portion was frozen immediately in liquid nitrogen,
whereas a second portion was fixed in 4% paraformaldehyde. Circu-
lating amino acid concentrations were measured in the sera of mice
killed 12 h after the last injection of asparaginase. Serum samples
were analyzed by the Indiana University School of Medicine Quan-
titative Amino Acid Core Facility as previously described (3).
Histology. Tissues fixed in 4% paraformaldehyde were frozen and
then sectioned (10 m) using a cryostat. Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assays were performed
using frozen sections and the Trevigen TACS 2 TdT-Blue Label In
Situ Apoptosis Detection kit (R&D Systems, Minneapolis, MN).
Digital images of equal-sized areas were captured and imported into
Scion Image for Windows (Scion, Frederick, MD). TUNEL-positive
cells were manually marked and counted using the counting tool as
previously reported (50). Frozen sections were also stained with Oil
Red O to visualize lipid content (50). Paraffin-embedded liver spec-
imens were sectioned (6 m) and stained with hematoxylin and eosin
to visualize general histology and identify histopathological features
under light microscopy.
Triglyceride measurements. Triglycerides were measured from
frozen liver tissue (40 mg) using the Biovision Colorimetric Tri-
glyceride Quantification kit (Mountain View, CA) following to the
manufacturer’s instructions exactly as previously detailed (50).
Immunoblot analysis. Weighed, frozen tissues were transferred to
microfuge tubes on ice and homogenized in 7 volumes of solution
consisting of 20 mM N-2-hydroxyethylpiperazine-N=-2-ethanesul-
fonic acid (pH 7.4), 100 mM KCl, 0.2 mM EDTA, 2 mM EGTA, 1
mM dithiothreitol, 50 mM sodium fluoride, 50 mM -glycerophos-
phate, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine,
and 0.5 mM sodium orthovanadate. The homogenates were immedi-
ately clarified by centrifugation at 10,000 g for 10 min at 4°C, and
measurements of indicated protein levels and phosphorylation states
were carried out as previously described (13). Phosphorylation of eIF2
was assessed using an antibody that recognizes the -subunit only
when it is phosphorylated at serine-51 (Cell Signaling Technology,
Beverly, MA); results were normalized for total eIF2 levels with an
antibody that recognizes the protein irrespective of phosphorylation
state (Santa Cruz Biotechnology, Santa Cruz, CA). Phosphorylation of
4E-BP1 and S6K1 was measured using polyclonal antibodies specific
to each (Bethyl, Montgomery, TX). Phosphorylation of mTOR at
serine-2448 and Raptor at serine-473 was measured using polyclonal
antibodies (Cell Signaling Technology); results were corrected for
total protein expression with antibodies that recognize the protein
irrespective of phosphorylation state (Cell Signaling Technology).
Caspase-3 cleavage was evaluated by expressing the amount of the
cleaved form as a ratio to the pro-version of caspase-3, using poly-
clonal antibodies (Cell Signaling Technology). Poly(ADP) ribose
polymerase (PARP) Antibody was used to detect endogenous levels
of full-length PARP1 (116 kDa), as well as the large fragment (89
kDa) of PARP1 resulting from caspase cleavage. The antibody does
not cross-react with related proteins or other PARP isoforms (Cell
Signaling Technology). Blots were developed with enhanced chemi-
luminesence (Amersham Biosciences). Protein expression was ana-
lyzed using a Carestream 4000MM multimodal imager, and band
Table 1. Food intake and body and tissue weights in wild-type and GCN2 null mice treated with asparaginase or PBS
WP WA GP GA Strain Treatment Strain  Treatment
Food intake, g/day 3.06	 0.18A 2.90 	 0.10A 3.01 	 0.05A 1.97 	 0.18B Yes Yes Yes
Body wt change, g 0.58 	 0.19A 0.82 	 0.38B 0.28 	 0.66A 2.59 	 0.45B Yes Yes Yes
Body wt, %change 3.22	 1.10A 4.18 	 2.13B 1.44 	 3.57A 14.21 	 2.70B Yes Yes Yes
Liver wt, g 0.91 	 0.09 0.76 	 0.02 1.18	 0.07 0.77 	 0.05 No Yes No
Liver wt, %body wt 4.99	 0.12 4.42 	 0.15 5.26	 0.23 4.47 	 0.22 No Yes No
Muscle wt, g 0.18 	 0.02 0.18 	 0.01 0.16	 0.01 0.14 	 0.01 No No No
Muscle wt, %body wt 0.97	 0.04 1.02 	 0.04 0.92	 0.03 0.94 	 0.02 No No No
Values are means	 SE; n
 5–8 mice/group. GCN2, general control nonderepressible kinase 2; yes, significant main effect P 0.05; no, not significant P 0.05;
WP, wild-type mice given PBS; WA, wild-type mice given asparaginase; GP, Gcn2/mice given PBS; GA, Gcn2/mice given asparaginase. When significant effects
were present, differences among treatment groups were assessed with LSD post hoc test. Labeled means without a common letter differ (P  0.05, LSD post hoc test).
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density was quantitated using Carestream Molecular Imaging Soft-
ware (version 5.0).
Quantitative real-time PCR. Total RNA was extracted from frozen
tissue using TriReagent (Molecular Research Center, Cincinnati, OH)
followed by DNase treatment (VersaGene DNase kit; Gentra Sys-
tems) (13). The A260/280 ratio was between 1.8 and 2.0 following
RNA purification using the RNeasy mini kit (Qiagen). Levels of
mRNAs were determined by quantitative PCR using TaqMan re-
agents. In this PCR assay, 1 g of the purified RNA solutions was
used for reverse transcription, which was carried out utilizing the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA). TaqMan Gene Expression Master Mix and
TaqMan Gene Expression Assays (Applied Biosystems) were then
used to conduct the quantitative PCR. Amplification and detection
were performed using the StepOnePlus Real-Time PCR System (Ap-
plied Biosystems) (13). Each mRNA from a single biological sample
was measured in triplicate and normalized to 18S ribosomal RNA. A
subset of samples evaluated in parallel using -actin as an additional
internal control delivered similar results. Results were obtained by the
comparative Ct method and are expressed as fold change with respect
to the experimental control.
Statistics. Experimental results were analyzed using SPSS Statistics
software (IBM). Data were analyzed using two-way ANOVA to
assess main vs. interaction effects, with drug treatment and mouse
strain as independent variables. When main or interaction effects were
significant, differences between individual treatment groups were
assessed using the LSD post hoc test. The data presented are ex-
pressed as means 	 SE. The level of significance was set at P  0.05
for all statistical tests. No significant differences were found between
sexes; therefore, data were combined for male and female mice.
RESULTS
Food intake, body and tissue weights, and circulating amino
acids are impacted differently in wild-type vs. Gcn2 null mice
treated with asparaginase. We assessed the role of GCN2 in
the mechanism by which asparaginase causes liver toxicity by
injecting the drug into wild-type and Gcn2 null mice one time
daily for 6 days and comparing outcomes with excipient-
treated mice. Average body weights were similar at the start of
the experiment (WP: 17.4 	 1.3; WA: 18.2 	 0.9; GP: 18.6 	
0.9; and GA: 18.7 	 0.7). Asparaginase treatment reduced
body weight gain and liver mass (2-way ANOVA P  0.05
main effect for drug) but not muscle mass (Table 1). These
effects were amplified in GA mice who experienced an 14%
loss in body weight relative to GP mice (Table 1). GA mice
consumed significantly less food than other mice; differences
in food intake explained a majority of the variance in body
weight among mice (R2 
 0.51). Recent experiments in which
WP and WA mice were pair-fed to the intake of GA mice for
8 days indicate that differences in body weights are reflected in
the body fat, and the reduction in food intake does not aggra-
vate liver toxicity by asparaginase (unpublished observations).
Circulating concentrations of amino acids were measured to
confirm asparagine depletion by drug and to assess whole body
amino acid metabolism (Table 2). As anticipated, plasma aspar-
agine was decreased in both WA and GA following drug treat-
ment to levels below the instrument detection threshold. However,
Table 2. Serum amino acids1,2 in wild-type or Gcn2 null mice treated with asparaginase or PBS for 6 days
Amino acid WP WA GP GA Strain Treatment Strain  Treatment
Asparagine 30.9	 2.45 BDL 28.60	 4.77 BDL NA NA NA
Aspartic acid 17.8	 1.54 39.50 	 7.03 25.40	 4.77 30.68 	 7.49 No Yes No
Glutamine 614.57	 28.64 682.20 	 22.34 608.13	 38.31 904.17 	 178.42 No Yes No
Glutamic acid 75.48	 3.96C 118.24 	 10.50B 82.65 	 5.31C 207.18 	 20.89A Yes Yes Yes
Threonine 165.88	 15.81B 222.30 	 25.49B 170.47 	 9.56B 464.63 	 51.72A Yes Yes Yes
Serine 115.20	 5.10B 152.20 	 12.02B 116.52 	 11.92B 312.12 	 57.26A Yes Yes Yes
Glycine 310.08	 18.59B 403.16 	 18.65A 250.35 	 17.93B 462.28 	 47.68A No Yes Yes
Alanine 353.93	 29.90B 423.96 	 43.80B 356.87 	 32.34B 917.40 	 126.85A Yes Yes Yes
Valine 256.57	 24.95B 293.00 	 35.70B 277.43 	 17.44B 441.28 	 36.13A Yes Yes Yes
Methionine 51.48	 3.56B 61.44 	 6.29B 47.08 	 3.01B 108.78 	 12.59A Yes Yes Yes
Isoleucine 81.62	 6.33B 89.56 	 9.00B 84.43 	 6.31B 123.73 	 10.03A Yes Yes Yes
Leucine 164.32	 13.93B 185.54 	 22.25B 166.05 	 13.82B 265.60 	 21.07A Yes Yes Yes
Tryptophan 205.37	 8.25 211.46 	 10.93 227.8 	 19.00 253.27 	 17.44 Yes No No
Lysine 303.97	 34.58C 394.60 	 29.24B 289.30 	 17.31C 528.50 	 33.90A Yes Yes Yes
Histidine 87.65	 8.77 117.58 	 7.88 111.42	 3.82 133.23 	 16.90 No Yes No
Arginine 149.83	 15.40 187.90 	 16.83 132.53	 12.61 230.68 	 26.14 No Yes No
Proline 79.73	 8.52B 107.86 	 16.38B 79.97 	 10.32B 195.78 	 22.75A Yes Yes Yes
Cystine 3.88	 1.56 1.52 	 0.16 8.78 	 1.54 8.65 	 3.90 Yes No No
Values are means 	 SE, n 
 5–8 mice/group. 1Plasma amino acids expressed as mol/l; 2when a strain  treatment interaction was significant, differences
among treatment groups were assessed with LSD post hoc test. Labeled means without a common letter differ (P  0.05, LSD post hoc test). yes, Significant
main effect P  0.05; no, not significant P  0.05; NA, not assessed; BDL, below detection limits.
Fig. 1. Lipid accumulation and DNA damage are amplified in the livers of general control nonderepressible kinase 2 (Gcn2) null mice treated with asparaginase
for 6 days. A: paraffin-embedded liver sections (6 m) were stained with hematoxylin and eosin, and images were taken using a20 objective to visualize general
cellular structure. An additional digital 2 zoom is provided in the top right corner of each image. B: neutral lipid content of liver was examined by Oil Red
O stain, and images were captured using a 20 objective (left). Liver triglyceride concentrations were also assessed biochemically (right). C: terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis was carried out on frozen liver sections (10 m), and digital images (left) captured using
a 20 objective were examined for DNA damage by counting TUNEL-positive nuclei in equal-sized fields of view (right). Values are means 	 SE, n 
 5–8
animals/group. Labeled means without a common letter differ (P  0.05). WP, wild-type mice given PBS; WA, wild-type mice given asparaginase; GP, Gcn2
null mice given PBS; GA, Gcn2 null mice given asparaginase.
E1126 GCN2 PROTECTS AGAINST HEPATOTOXICITY BY ASPARAGINASE
AJP-Endocrinol Metab • doi:10.1152/ajpendo.00080.2013 • www.ajpendo.org
 by 10.220.33.5 on Decem
ber 22, 2016
http://ajpendo.physiology.org/
D
ow
nloaded from
 
plasma glutamine was not reduced in WA mice and was signifi-
cantly elevated in drug-treated mice. In addition, circulating con-
centrations of most measured amino acids were highest in GA
mice after 6 days of treatment.
Lipid accumulation and DNA damage are amplified in the
livers of Gcn2 null mice treated with asparaginase. To com-
pare the histopathology resulting from asparaginase treatment
in wild-type vs. Gcn2 knockout mice, fixed liver samples were
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sectioned and stained to examine neutral lipid content and
general cellular structure using light microscopy. Hepatocytes
from WA mice showed the presence of cytosolic vacuoles
(Fig. 1A) and moderate Oil Red O staining (Fig. 1B, left), sug-
gesting lipid accumulation. These histological features were
also present in liver sections from GA mice, with GA liver
sections showing greater numbers of vacuoles and darker Oil
Red O staining accompanied by an 50% increase in triglyc-
eride concentrations compared with WP mice (Fig. 1B, right).
The appearance of swollen cells with fragmented or condensed
nuclei in GA sections prompted us to investigate the presence
of DNA damage. To address this, a TUNEL assay was per-
formed on frozen liver sections to identify the presence of
fragmented DNA. The number of TUNEL-positive nuclei
(2-way ANOVA interaction P  0.05) (Fig. 1C) was at least
2.5-fold greater in GA mice compared with wild-type mice
treated with drug. Despite the presence of large numbers of
TUNEL-positive nuclei in GA liver sections, activation of
apoptosis via caspase-3 and PARP cleavage was not indicated
(Fig. 2, H and I).
Asparaginase activates the GCN2-eIF2-AAR pathway, but
not the unfolded protein response in liver. AAR targets down-
stream of activated GCN2 were measured in the livers of
wild-type and Gcn2 knockout mice treated with asparaginase.
Phosphorylation at serine-51 on the -subunit of eIF2 was
sharply increased in WA mice compared with WP controls
(Fig. 2A). While attempts to detect ATF4 protein in whole liver
using commercial antibodies were not met with success,
mRNA levels for Atf4 (Fig. 2B) and those for ATF4 target
genes, asparagine synthetase (Asns) and CAAT enhancer-
binding protein homologous protein (Chop), were collectively
increased in WA compared with WP (Fig. 2, C and D). Loss of
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Fig. 2. Asparaginase activates the GCN2-eukaryotic initiation factor 2 (eIF2)-amino acid stress response (AAR) pathway but not the unfolded protein response
(UPR) in the liver. A: levels of phosphorylation of the -subunit (serine-51) of eIF2 were measured by immunoblot analysis. Results shown beneath the
representative immunoblot are expressed as the density of phosphorylated eIF2 relative to total levels of eIF2 -subunit. B–F: quantitative real-time PCR was
employed to measure mRNA expression of activating transcription factor 4 (Atf4, B), asparagine synthetase (Asns, C), CAAT enhancer-binding protein
homologous protein (Chop, D), Bip (E), and Gadd34 (G). X box-binding protein 1 (Xbp1) mRNA splicing (F) was assessed by determining the amount of the
spliced transcript relative to total Xbp1 mRNA levels as judged by qualitative PCR. H: cleavage of caspase-3 was assessed by immunoblot analysis with results
representing the density of the cleaved form of caspase-3 relative to pro-caspase-3. I: cleavage of poly(ADP) ribose polymerase (PARP) was assessed by
immunoblot analysis with results representing the density of the cleaved form of PARP relative to total PARP. Values are means 	 SE, n 
 5–8/group. Labeled
means without a common letter differ (P  0.05).
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GCN2 precluded eIF2 phosphorylation (Fig. 2A) and blocked
or significantly blunted mRNA expression of Atf4, Asns, and
Chop to asparaginase (Fig. 2, B–D). The small but significant
induction of Chop mRNA in GA is consistent with our previ-
ous work showing that a rapamycin-sensitive input contributes
to Chop expression (13). Finally, another member of the AAR
is GADD34, which functions in feedback dephosphorylation of
eIF2 (16, 41). GADD34 has suggested proapoptotic function
and was originally identified to be induced by DNA damage
and can be a target gene of both the ATF4 and CHOP
transcription factors in the AAR (28, 37, 39, 59). Whereas the
levels of Gadd34 transcripts were not significantly affected in
WA mice, there was 2.5-fold increase in GA livers at both 1
and 6 days (Fig. 2G and data not shown). These results support
the idea that GCN2 is the primary eIF2 kinase that is activated
upon chronic asparaginase therapy, and activation of GCN2
serves to reprogram gene expression to manage amino acid
stress.
A disruption in ER homeostasis can lead to an accumulation
of misfolded proteins in this organelle, which activates an
adaptive pathway called the unfolded protein response (UPR)
(38, 53). A sensor of unfolded proteins in the ER lumen is the
type 1 ER transmembrane protein kinase called IRE1. Activa-
tion of IRE1 unleashes endoribonuclease activity that facili-
tates splicing of X box-binding protein 1 (Xbp1) mRNA. This
unconventional splicing reaction produces a potent transcrip-
tion factor that activates UPR genes important for recovery and
adaptation to ER stress. The molecular chaperone BiP/GRP78
serves as another marker of ER stress, for its transcriptional
expression is increased under conditions of accumulating mis-
folded proteins. Increased Xbp1 mRNA splicing and Bip
mRNA expression is reported in the liver of mice treated with
the ER stress agent tunicamycin (50). In contrast, no changes
in Xbp1 mRNA splicing or Bip transcript levels were observed
according to mouse strain or asparaginase treatment (Fig. 2, E
and F). These results suggest that asparaginase treatment does
not activate the UPR and that ER stress is not significantly
involved in the development of hepatotoxicity in Gcn2 null
mice.
GCN2 deletion alters mTORC1 signaling in the livers of
asparaginase-treated mice. Changes in signaling via the
mTORC1 pathway were addressed to determine how aspara-
ginase affected the other major amino acid-sensing pathway. In
WA, there were no significant changes in phosphorylation of
mTOR at serine-2448 (Fig. 3A) nor changes in the phosphor-
ylation of the mTOR regulatory factor Raptor (data not
shown), or the translational inhibitor and mTORC1 substrate
4E-BP1 (Fig. 3C). However, asparaginase treatment signifi-
cantly increased phosphorylation of the mTORC1 target S6K1
independent of GCN2 status (2-way ANOVA P  0.05 main
effect for treatment) and both serine-2448 phosphorylation of
mTORC1 and S6K1 phosphorylation tended to be highest in
GA (Fig. 3B). On the other hand, the levels of total 4E-BP1
mRNA and protein were significantly increased by asparagi-
nase (Fig. 3C), an effect that was GCN2-dependent.
Activation of mTORC1 signaling is associated with inhibi-
tion of autophagy. However, no changes were identified in
mRNA expression of two important regulators of autophagy,
LC3B and p62 (data not shown). Regulation of the ubiquitin-
proteosome pathways was also examined. No changes in
mRNA expression of Psma2, a component of the 20S catalytic
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Fig. 3. Asparaginase activates mammalian target of rapamycin complex 1
(mTORC1) signaling in the livers of Gcn2 null mice. A: immunoblot analysis
was used to assess phosphorylation of mTOR at serine-2448. A representative
immunoblot is shown above data averages. B: phosphorylation of ribosomal
protein S6 kinase (S6K1) was assessed by gel shift, calculating the density of
the slower-migrating form(s) relative to all bands combined. A representative
immunoblot is shown above data averages. C: immunoblot analysis was used
to assess eIF-4E-binding protein 1 (4E-BP1) protein expression (top), and
quantitative real-time PCR was employed to examine mRNA expression of
4E-BP1 (bottom). Values are means 	 SE, n 
 5–8/group. Labeled means
without a common letter differ (P  0.05).
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subunit of the proteasome, or in mRNA expression of the E3
ubiquitin ligase called Atrogen1 were noted across experimen-
tal treatment groups (data not shown).
GCN2 deletion compromises oxidative defenses during as-
paraginase, promoting inflammatory stress. The antioxidant
function of eIF2 phosphorylation and a tight linkage between
ATF4 and cellular oxidative defenses is reported (24, 36). As
such, we measured the impact of asparagainse on oxidative
defense genes superoxide dismutase (Sod2) and glutathione per-
oxidase (Gpx1) in the presence vs. absence of Gcn2. Expression
of Sod2 was increased approximately twofold in GA but not WA
livers at 1 and 6 days (Fig. 4, A and B). Likewise, the levels of
Gpx1 mRNA, encoding one of the most important endogenous
antioxidants, was increased in GA livers at 1 day (2-fold
increase) and then significantly decreased relative to control at 6
days (3-fold decrease) (Fig. 4, C and D). Collectively, these
results suggest that Gcn2 deletion compromises oxidative de-
fenses during asparaginase treatment.
Given that oxidative stress can promote chronic inflamma-
tion, mRNA expression of the proinflammatory cytokine Tnf-
was examined in the livers of wild-type and Gcn2 null mice
treated with asparaginase (Fig. 4, E and F). In the liver of GA
mice, a small increase in levels of Tnf- mRNA following one
injection (3-fold) preceded much larger increases (8 fold)
in liver following 6 days of injections. These data are consis-
tent with the idea that, during asparaginase treatment, deletion
of Gcn2 predisposes the liver toward DNA damage via oxida-
tive stress and inflammation.
DISCUSSION
This study demonstrates that GCN2 is critically important in
the ability of the liver to limit toxicity by asparaginase. Livers
from mice deleted for Gcn2 display inflammation, steatosis,
and degeneration following drug treatment. By comparison,
each of these outcomes was not present or was significantly
mitigated in wild-type mice treated with asparaginase, suggest-
ing that the GCN2-eIF2-AAR pathway serves to protect the
liver during asparaginase treatment.
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Fig. 4. Asparaginase increases markers of ox-
idative damage and inflammation after one and
six daily injections. Quantitative real-time PCR
was employed to examine mRNA expression
of superoxide dismutase (Sod2, A and B), glu-
tathione peroxidase (Gpx1, C and D), and
Tnf- (E and F) after 1 (left) and 6 (right) days
of injections with asparaginase or PBS. Values
are means 	 SE, n 
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Gcn2 null mice treated with asparaginase demonstrate in-
creased DNA damage in the liver, indicating activation of cell
death pathways. However, the absence of caspase-3 and PARP
cleavage suggests that the classical form of apoptosis is not
triggered at this point in time. Perhaps additional treat-
ment days would induce this pathway; alternatively, a caspase-
independent death pathway, such as autophagy/mitophagy, onco-
sis, paraptosis, or necrosis (34, 35, 55), may be activated. Cell
death without caspase activation is not uncommon, particularly
with chemotherapy drugs. For example, TNF--mediated liver
injury by concanavalin A reportedly follows a caspase-3-
independent necrotic path (33). Considering the increase in Tnf-
occurred alongside no indication that autophagy, proteasome
activity, and/or the UPR are induced, a necrotic form of pro-
grammed cell death appears reasonable. Nonetheless, extending
the time period of asparaginase treatment to clarify this point is
warranted.
Previously we reported that the lowered liver protein synthesis
in mice subjected to amino acid deprivation is substantially
alleviated upon deletion of Gcn2 (3). In this study, both the AAR
and the mTORC1 pathways in the liver of Gcn2 null mice treated
with asparaginase reflect a pattern of signaling and gene expres-
sion that is consistent with a restoration of liver protein synthesis.
A premature restoration in protein synthesis can direct cell fate
toward cell death pathways during ER stress (22, 39). Overex-
pression of ATF4 and CHOP in mouse liver or overexpression of
GADD34 in mouse embryonic fibroblasts increases protein syn-
thesis but reduces survival via increased production of reactive
oxygen species (22). In the current study, increased expression of
the eIF2 phosphatase GADD34 alongside increased mTOR-S6K1
signaling would promote protein synthesis inappropriately. Re-
duced transcription of the translational inhibitor 4E-BP1, critical
to cell survival during ER stress (51, 58), would further allow for
translation initiation to continue, generating reactive oxygen spe-
cies. The ability of the cell to detoxify these damaging agents
depends on appropriate expression of antioxidant genes such as
Sod2 and Gpx1. Interestingly, Gcn2 knockout mice fed a leucine-
imbalanced diet demonstrate a decrease in hepatic Gpx1 mRNA
expression (15), similar to Gcn2 null mice treated with asparagi-
nase in the current study. Collectively, these data support the
concept that the GCN2-eIF2-AAR is an important regulator of
cellular redox state and that a chronic imbalance in oxidative
defenses during asparaginase treatment may facilitate inflamma-
tory-mediated death pathways in the liver.
In our previous studies, a single injection of E. coli aspara-
ginase significantly reduces circulating and hepatic concentra-
tions of glutamine alongside liver protein synthesis rates (44).
In the present study, depletion of circulating glutamine is not
sustained, suggesting that glutamine synthesis is increased.
Furthermore, circulating concentrations of glutamine are high-
est in Gcn2 null mice treated with asparaginase. These data
lead us to speculate that individuals with a defect in the AAR
pathway could be at greater risk of drug resistance along with
increased drug toxicity if the defect promotes glutamine syn-
thesis. Two lines of evidence provide support for this thought.
The first is a report demonstrating that obese children treated
with asparaginase have greater rates of drug resistance and
relapse because of bone marrow adipocytes releasing more
glutamine via glutamine synthetase induction (19). The impli-
cation is that factors that increase glutamine availability thwart
asparaginase efficacy. Certainly our lab and others demonstrate
that glutamine availability benefits healthy tissues (14, 42, 44).
However, this concept must be considered on balance with a
need for glutamine depletion to achieve optimal tumor-killing.
The second line of evidence is a human study linking ALL
treatment outcome to polymorphisms in the ATF5 gene that
regulate its promoter activity and expression (47). ATF5 is both
a target of ATF4-directed transcription and is also subject to
translational control in response to eIF2 phosphorylation (7,
61). The impact of ATF5 polymorphisms on glutamine and
asparagine synthesis is unknown. As shown in this study as
well as others, induction of Asns following asparaginase is an
AAR-driven response (32, 45, 49). Less is known concerning
glutamine synthetase expression or activity in response to
asparaginase in vivo. Protein but not mRNA expression of
glutamine synthetase is increased in liver and muscle cells
incubated in the absence of glutamine (29, 54), whereas en-
zyme activity is minimally impacted (57). In tumor cells,
glutamine synthetase activity can be increased by asparaginase,
leading to drug resistance (5, 46). How whole body glutamine
metabolism is regulated by the GCN2-mediated AAR requires
further study.
Aside from reducing serum asparagine, asparaginase tended
to increase circulating concentrations of most amino acids and,
similar to dietary leucine deprivation, Gcn2 null mice treated
with asparaginase showed significantly increased circulating
essential amino acids (3). The reason for these changes is
unknown, although increased muscle breakdown seems un-
likely, since muscle mass stayed in proportion to body weight.
Higher liver protein turnover was also postulated, but investi-
gation into markers of protein degradation reflecting the ubiq-
uitin proteasome pathway (PSMA2 and atrogin1) and the
lysosomal pathway (LC3B) revealed no differences in gene
expression according to drug treatment or GCN2 status. Al-
though we do not yet understand the basis for elevations in
circulating amino acids, we speculate that these increases
provide an anabolic signal via mTORC1, and this in combina-
tion with Gcn2 deletion inappropriately elevates liver protein
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Fig. 5. The GCN2-initiated AAR promotes liver recovery during asparaginase
treatment. The current working model shows that, in the absence of GCN2,
both a premature restoration of protein synthesis alongside a failure to induce
gene transcription by ATF4 alters the cellular redox environment, favoring a
proinflammatory state and facilitating DNA damage and cell death.
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synthesis. Previous studies suggest that premature activation of
protein synthesis promotes cell death pathways through in-
creased production of reactive oxygen species (22, 39). Our
results showing altered antioxidant genes, proinflammatory
cytokine induction, and DNA damage are consistent with the
idea that an inability to dampen protein synthesis during amino
acid stress alters cellular redox conditions unfavorably and
leads to cell damage via inflammatory stress (Fig. 5).
In summary, mice deficient in Gcn2 are unable to induce the
AAR and suffer a greater degree of hepatotoxicity when given
asparaginase. An important topic for future studies is address-
ing the incidence and influence of genetic polymorphisms that
affect the efficacy of the GCN2-AAR pathway during aspara-
ginase treatment. A more complete understanding of the AAR
response to asparaginase may facilitate the development of a
more targeted treatment regimen for patients diagnosed with
ALL.
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